Omid Zarei1,2,3, Silvia Benvenuti4, Fulya Ustun-Alkan5, Maryam Hamzeh-Mivehroud6,7, Siavoush Dastmalchi8,9. 1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Molecular Therapeutics and Exploratory Research Laboratory, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Turin, Italy. 5. Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Istanbul University, Istanbul, Turkey. 6. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. hamzehm@tbzmed.ac.ir. 7. Department of Medicinal Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. hamzehm@tbzmed.ac.ir. 8. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. dastmalchi.s@tbzmed.ac.ir. 9. Department of Medicinal Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. dastmalchi.s@tbzmed.ac.ir.
Abstract
PURPOSE: Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d'Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery. METHODS: In this review, we will summarize the available agents against extracellular domain of RON with potential antitumor activities. RESULTS: The presented antibodies and antibody drug conjugates against RON in this review showed wide spectrum of in vitro and in vivo antitumor activities promising the hope for them entering the clinical trials. CONCLUSION: Due to critical role of extracellular domain of RON in receptor activation, the development of therapeutic agents against this region could lead to fruitful outcome in cancer therapy.
PURPOSE:Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d'Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery. METHODS: In this review, we will summarize the available agents against extracellular domain of RON with potential antitumor activities. RESULTS: The presented antibodies and antibody drug conjugates against RON in this review showed wide spectrum of in vitro and in vivo antitumor activities promising the hope for them entering the clinical trials. CONCLUSION: Due to critical role of extracellular domain of RON in receptor activation, the development of therapeutic agents against this region could lead to fruitful outcome in cancer therapy.
Authors: Silvia Benvenuti; Luca Lazzari; Addolorata Arnesano; Giulia Li Chiavi; Alessandra Gentile; Paolo M Comoglio Journal: Cancer Res Date: 2011-01-06 Impact factor: 12.701
Authors: Raffaella De Maria; Piera Maggiora; Bartolomeo Biolatti; Maria Prat; Paolo M Comoglio; Massimo Castagnaro; Maria Flavia Di Renzo Journal: Oncogene Date: 2002-03-07 Impact factor: 9.867
Authors: P Goyette; C Lefebvre; A Ng; S R Brant; J H Cho; R H Duerr; M S Silverberg; K D Taylor; A Latiano; G Aumais; C Deslandres; G Jobin; V Annese; M J Daly; R J Xavier; J D Rioux Journal: Mucosal Immunol Date: 2008-01-16 Impact factor: 7.313
Authors: G Gaudino; A Follenzi; L Naldini; C Collesi; M Santoro; K A Gallo; P J Godowski; P M Comoglio Journal: EMBO J Date: 1994-08-01 Impact factor: 11.598
Authors: Melissa Milan; Silvia Benvenuti; Alice Maria Balderacchi; Anna Rita Virzì; Alessandra Gentile; Rebecca Senetta; Paola Cassoni; Paolo Maria Comoglio; Giulia Maria Stella Journal: ERJ Open Res Date: 2018-03-06